Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review
Mesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a low-frequency driver mutation in metastatic non-small cell lung cancer (NSCLC) (3%–4%) and is associated with a poor prognosis. With the advent of selective MET inhibitors such as capmatinib, tepotinib, and savolitinib,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1006634/full |
| _version_ | 1811257527238656000 |
|---|---|
| author | Jiangfang Tian Zhen Lin Yueyun Chen Yang Fu Zhenyu Ding |
| author_facet | Jiangfang Tian Zhen Lin Yueyun Chen Yang Fu Zhenyu Ding |
| author_sort | Jiangfang Tian |
| collection | DOAJ |
| description | Mesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a low-frequency driver mutation in metastatic non-small cell lung cancer (NSCLC) (3%–4%) and is associated with a poor prognosis. With the advent of selective MET inhibitors such as capmatinib, tepotinib, and savolitinib, the outcome for these patients was significantly improved. Here, we report a 76-year-old male patient with marginally resectable stage IIIB lung adenocarcinoma harboring METex14 who was successfully treated with savolitinib for neoadjuvant therapy. An 82% shrinkage of the primary tumor was observed, and only 5% of the tumor was viable by pathology in the following radical surgery. A dozen of studies tested the efficiency of neoadjuvant immunotherapy or immunochemotherapy, but for NSCLC with driver mutations, neoadjuvant targeted therapy might be more appropriate. We advocated the neoadjuvant MET TKI treatment for NSCLC. |
| first_indexed | 2024-04-12T17:57:49Z |
| format | Article |
| id | doaj.art-d00152490d5446b5ba3474324cdaf66e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T17:57:49Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d00152490d5446b5ba3474324cdaf66e2022-12-22T03:22:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-10-011210.3389/fonc.2022.10066341006634Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature reviewJiangfang TianZhen LinYueyun ChenYang FuZhenyu DingMesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a low-frequency driver mutation in metastatic non-small cell lung cancer (NSCLC) (3%–4%) and is associated with a poor prognosis. With the advent of selective MET inhibitors such as capmatinib, tepotinib, and savolitinib, the outcome for these patients was significantly improved. Here, we report a 76-year-old male patient with marginally resectable stage IIIB lung adenocarcinoma harboring METex14 who was successfully treated with savolitinib for neoadjuvant therapy. An 82% shrinkage of the primary tumor was observed, and only 5% of the tumor was viable by pathology in the following radical surgery. A dozen of studies tested the efficiency of neoadjuvant immunotherapy or immunochemotherapy, but for NSCLC with driver mutations, neoadjuvant targeted therapy might be more appropriate. We advocated the neoadjuvant MET TKI treatment for NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2022.1006634/fullneoadjuvant therapysavolitinibMET exon 14 skipping mutation (METex14)NSCLCcase reportmajor pathological response |
| spellingShingle | Jiangfang Tian Zhen Lin Yueyun Chen Yang Fu Zhenyu Ding Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review Frontiers in Oncology neoadjuvant therapy savolitinib MET exon 14 skipping mutation (METex14) NSCLC case report major pathological response |
| title | Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review |
| title_full | Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review |
| title_fullStr | Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review |
| title_full_unstemmed | Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review |
| title_short | Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review |
| title_sort | dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with met exon 14 skipping mutation a case report and literature review |
| topic | neoadjuvant therapy savolitinib MET exon 14 skipping mutation (METex14) NSCLC case report major pathological response |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1006634/full |
| work_keys_str_mv | AT jiangfangtian dramaticresponsetoneoadjuvantsavolitinibinmarginallyresectablelungadenocarcinomawithmetexon14skippingmutationacasereportandliteraturereview AT zhenlin dramaticresponsetoneoadjuvantsavolitinibinmarginallyresectablelungadenocarcinomawithmetexon14skippingmutationacasereportandliteraturereview AT yueyunchen dramaticresponsetoneoadjuvantsavolitinibinmarginallyresectablelungadenocarcinomawithmetexon14skippingmutationacasereportandliteraturereview AT yangfu dramaticresponsetoneoadjuvantsavolitinibinmarginallyresectablelungadenocarcinomawithmetexon14skippingmutationacasereportandliteraturereview AT zhenyuding dramaticresponsetoneoadjuvantsavolitinibinmarginallyresectablelungadenocarcinomawithmetexon14skippingmutationacasereportandliteraturereview |